| Name | Title | Contact Details |
|---|
Micropulse, Inc., located 30 miles east of the Orthopaedic Capital of the World, has been serving the Medical Device Industry as a manufacturer of orthopaedic instruments and implants since 1988. Although Micropulse was founded as a precision tooling
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Our vision is to free diabetics from the painful finger prick and throughout this leverage for our shareholders the significant market potential that such a non-invasive glucose monitor could achieve.
Vivosonic Inc. is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Medi-Globe Corporation is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.